(Q45079359)

English

Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective

scientific article published in January 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

0 references

author name string

Peter K Schädlich

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Josef Georg Brecht

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Badrudin Rangoonwala

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Eduard Huppertz

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

955-973

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

https://scigraph.springernature.com/pub.10.2165/00019053-200422150-00001

0 references

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Cost effectiveness of ramipril treatment for cardiovascular risk reduction

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Costs of type 2 diabetes in Germany. Results of the CODE-2 study

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

The future of pharmacoeconomics: a commentary

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Economic impact of ramipril on hospitalization of high-risk cardiovascular patients

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Blood-pressure reduction and cardiovascular risk in HOPE study

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

The HOPE study: comparison with other trials of secondary prevention

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Physicians' interpretation of "class effects": a need for thoughtful re-evaluation

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Ramipril for the prevention and treatment of cardiovascular disease

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422150-00001

21 January 2018

[Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study]

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial]

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigat

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Costs of coronary heart diseases over the remaining life time in coronary heart disease cases--an analysis of the current status of coronary heart disease cases in Germany from the social perspective]

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Economic analysis of secondary prevention of coronary heart disease with simvastatin (Zocor) in Germany]

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence-based medicine and ACE inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The anti-ischemic potential of angiotensin-converting enzyme inhibition: insights from the heart outcomes prevention evaluation trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Cost-effectiveness analysis of prevention of reinfarction using low-dose acetylsalicylic acid; model calculation]

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Class effects and evidence-based medicine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Recommendations of the German Society of Clinical Pharmacology and Therapy for implementing and evaluating pharmaco-economic studies]

1 reference

https://pubmed.ncbi.nlm.nih.gov/15449961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00019053-200422150-00001

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45079359&oldid=2065311915"